Morningstar

Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX® for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety

FORT LEE, N.J., July 29, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Coagulation Factor X ...
Business Insider

BPL Announces the Kick-off of the Hereditary Factor X Deficiency in America Survey

DURHAM, N.C., Sept. 28, 2021 /PRNewswire/ -- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, with US offices in Durham, NC announced today the kick-off of ...
News Medical

European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

Bio Products Laboratory, Limited (BPL) today announced that the European Medicines Agency has granted marketing authorisation for Coagadex. Coagadex is indicated for the treatment and prophylaxis of ...
MarketWatch

Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX(R) for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety

The MarketWatch News Department was not involved in the creation of this content. FORT LEE, N.J., July 29, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce that the U.S. Food and Drug ...